Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?

Key PointsNovo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Wednesday 7 October →